SCHEMBL25301445

SCHEMBL25301445

COC(=O)C1CCN(c2ncc(C)c(C#N)n2)CC1F

nearest known ligand 0.40

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
RIPK1 Q13546 5/20 0.40
PIK3CD O00329 3/20 0.35
GPBAR1 Q8TDU6 1/20 0.35
CHRM4 P08173 2/20 0.35
KCNMA1 Q12791 1/20 0.35
KDM4E B2RXH2 2/20 0.34
CAMK1D Q8IU85 1/20 0.34
PIK3R1 P27986 1/20 0.33
MEN1 O00255 1/20 0.33
ALDH1A1 P00352 1/20 0.33
LMNA P02545 1/20 0.33
KMT2A Q03164 1/20 0.33
BRAF P15056 1/20 0.33
AR P10275 1/20 0.33
BTK Q06187 2/20 0.33
JAK3 P52333 1/20 0.33
SSTR2 P30874 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30338833 1.00 RIPK1 (0.40) RIPK1PIK3CDGPBAR1CHRM4KCNMA1
SCHEMBL25816759 0.82 BTK (0.37) RIPK1KDM4ECAMK1DBTK
SCHEMBL25818824 0.73 KDM4E (0.47) GPBAR1CHRM4KCNMA1KDM4EMEN1
SCHEMBL30547589 0.73 KDM4E (0.47) GPBAR1CHRM4KCNMA1KDM4EMEN1
SCHEMBL25294414 0.70 RBP4 (0.38) RIPK1KDM4ECAMK1DMEN1ALDH1A1
SCHEMBL25294415 0.70 RBP4 (0.38) RIPK1KDM4ECAMK1DMEN1ALDH1A1
SCHEMBL12578223 0.64 SLC6A2 (0.36)
SCHEMBL21867151 0.63 RIPK1 (0.53) RIPK1GPBAR1KDM4E
SCHEMBL25816606 0.63 KDM4E (0.49) KDM4EMEN1ALDH1A1LMNAKMT2A
SCHEMBL25254837 0.62 KDM4E (0.50) RIPK1GPBAR1CHRM4KDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116547281-A Isoxazolidines as RIPK1 inhibitors and uses thereof 赛诺菲 2023-08-04 CN disclosed
US-20230219937-A1 ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF SANOFI (FR) 2023-07-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230219937-A1 ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF RIPK1, RIPK4, RIPK2 RIPK1 1/4885PIK3CD 753/4885GPBAR1 908/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.